References
- Tasdemir E, Toptas T, Demir C, Esen R, Atmaca M. Aspirin resistance in patients with type II diabetes mellitus. Ups J Med Sci. 2014;119:25–31.
- Kotani K, Caccavello R, Hermo R, Yamada T, Taniguchi N, Gugliucci A. Serum cholesterol concentration associated with aspirin esterase activity in older people: preliminary data. Int J Med Sci. 2010;7:90–3.
- James S. Coagulation, inflammation and myocardial dysfunction in unstable coronary artery disease and the influence of glycoprotein IIb/IIIa inhibition and low molecular weight heparin. Ups J Med Sci. 2004;109:71–122.
- Larsen SB, Grove EL, Kristensen SD, Hvas AM. Reduced antiplatelet effect of aspirin is associated with low-grade inflammation in patients with coronary artery disease. Thromb Haemost. 2013;109:920–9.
- Yassine HN, Davis-Gorman G, Stump CS, Thomson SS, Peterson J, McDonagh PF. Clinical determinants of aspirin resistance in diabetes. Diabetes Res Clin Pract. 2010;90:e19–21.
- Kapłon-Cieślicka A, Rosiak M, Postuła M, Serafin A, Kondracka A, Opolski G, et al. Predictors of high platelet reactivity during aspirin treatment in patients with type 2 diabetes. Kardiol Pol. 2013;71:893–902.
- Zethelius B, Berglund L, Hänni A, Berne C. The interaction between impaired acute insulin response and insulin resistance predict type 2 diabetes and impairment of fasting glucose. Ups J Med Sci. 2008;113:117–29.
- Gao F, Wang ZX, Men JL, Ren J, Wei MX. Effect of polymorphism and type II diabetes on aspirin resistance in patients with unstable coronary artery disease. Chin Med J (Engl). 2011;124:1731–4.
- Pulcinelli FM, Pignatelli P, Celestini A, Riondino S, Gazzaniga PP, Violi F. Inhibition of platelet aggregation by aspirin progressively decreases in long-term treated patients. J Am Coll Cardiol. 2004;43:979–84.